Match the following neurocognitive or related psychiatric conditions with their most appropriate initial pharmacological management strategy or critical therapeutic constraint.
- Dementia with Lewy bodies (DLB) presenting with distressing visual hallucinationsHigh risk of severe sensitivity to typical antipsychotics; use pimavanserin or low-dose quetiapine if pharmacological management is mandatory.
- Behavioral variant frontotemporal dementia (bvFTD) presenting with severe impulsivityFirst-line pharmacological management targets behavioral symptoms (e.g., with SSRIs); cholinesterase inhibitors lack efficacy and may worsen agitation.
- Mild-to-moderate Alzheimer disease newly diagnosed in the outpatient settingFirst-line pharmacological management includes initiation of an acetylcholinesterase inhibitor (e.g., donepezil, rivastigmine).
- Major depressive disorder presenting with dementia-like cognitive impairment (pseudodementia)Primary treatment involves antidepressant therapy, which frequently reverses the associated cognitive deficits.
Answer
Dementia with Lewy bodies matches with neuroleptic sensitivity; Behavioral variant frontotemporal dementia matches with SSRI use for behaviors and avoiding cholinesterase inhibitors; Alzheimer disease matches with initiating acetylcholinesterase inhibitors; Pseudodementia matches with antidepressant therapy reversing cognitive deficits.
Each condition pairs with a unique and essential pharmacological principle: DLB requires avoiding typical antipsychotics, bvFTD relies on SSRIs while avoiding AChE inhibitors, Alzheimer disease is primarily treated with AChE inhibitors, and pseudodementia cognitive deficits are reversible with antidepressants.
Step-by-Step Solution
Key Concept
Pharmacological management and critical contraindications in major neurocognitive disorders